HEALTH-RELATED QUALITY OF LIFE AND HEALTH-STATE UTILITIES IN IGA NEPHROPATHY: A SYSTEMATIC LITERATURE REVIEW
Author(s)
Prashanth Kondaparthi, MSc1, Aneesh T. George, BDS, MSc1, Navya Sri Gurram, MSc1, Mark pletscher, PhD2, Nicholas Adlard, MA, MBA, MSc2.
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharma AG, Basel, Switzerland.
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharma AG, Basel, Switzerland.
OBJECTIVES: IgA nephropathy (IgAN) is a rare chronic kidney disease (CKD) characterized by progressive renal decline and significant patient burden. This systematic literature review examined health-related quality of life (HRQoL) and health-state utilities among patients with IgAN.
METHODS: A systematic search was performed in Embase, MEDLINE, and Cochrane Library from inception to 29th January 2026. Additionally, key conferences and health technology assessment websites were searched. Quality of the included studies was assessed using the National Institute for Health and Care Excellence Health State Utility Values scale. Publications were independently screened by two reviewers.
RESULTS: A total of 11 relevant studies were included with sample size and mean age ranging from 51 to 1,515 patients and 9.8 to 48.9 years. Quality of life worsened significantly with increasing proteinuria and declining kidney function across multiple HRQoL instruments (p<0.001). Among IgAN patients diagnosed with depression, a 6-month physical training program was associated with significantly higher Short Form-36 physical (47.5 vs 44.6; p=0.007) and mental component scores (49.6 vs 43.7; p<0.001) compared with the control group. Pediatric IgAN patients (N=51) reported lower mean physical well‑being scores than healthy peers (62.8 vs 70.2; p=0.055) based on Kidscreen‑52 assessment. Health-state utilities based on EuroQol 5‑Dimensions (EQ-5D-5L), EQ-VAS, and Time Trade-Off (TTO) methods were reported in two studies, showing a decline in utilities with increasing proteinuria and advancing CKD stages. Among IgAN patients with advanced CKD (stage 5), those receiving dialysis had significantly lower utility scores than those not yet on dialysis (EQ‑VAS: 0.22 vs 0.27; TTO: 0.38 vs 0.42; p<0.0001).
CONCLUSIONS: IgAN was associated with substantial HRQoL impairment. Available evidence indicates reduced utility values with increasing proteinuria and advancing CKD stages, indicating worsening with disease progression and emphasizing the need for targeted therapies that slow down disease progression and improve patient’s HRQoL.
METHODS: A systematic search was performed in Embase, MEDLINE, and Cochrane Library from inception to 29th January 2026. Additionally, key conferences and health technology assessment websites were searched. Quality of the included studies was assessed using the National Institute for Health and Care Excellence Health State Utility Values scale. Publications were independently screened by two reviewers.
RESULTS: A total of 11 relevant studies were included with sample size and mean age ranging from 51 to 1,515 patients and 9.8 to 48.9 years. Quality of life worsened significantly with increasing proteinuria and declining kidney function across multiple HRQoL instruments (p<0.001). Among IgAN patients diagnosed with depression, a 6-month physical training program was associated with significantly higher Short Form-36 physical (47.5 vs 44.6; p=0.007) and mental component scores (49.6 vs 43.7; p<0.001) compared with the control group. Pediatric IgAN patients (N=51) reported lower mean physical well‑being scores than healthy peers (62.8 vs 70.2; p=0.055) based on Kidscreen‑52 assessment. Health-state utilities based on EuroQol 5‑Dimensions (EQ-5D-5L), EQ-VAS, and Time Trade-Off (TTO) methods were reported in two studies, showing a decline in utilities with increasing proteinuria and advancing CKD stages. Among IgAN patients with advanced CKD (stage 5), those receiving dialysis had significantly lower utility scores than those not yet on dialysis (EQ‑VAS: 0.22 vs 0.27; TTO: 0.38 vs 0.42; p<0.0001).
CONCLUSIONS: IgAN was associated with substantial HRQoL impairment. Available evidence indicates reduced utility values with increasing proteinuria and advancing CKD stages, indicating worsening with disease progression and emphasizing the need for targeted therapies that slow down disease progression and improve patient’s HRQoL.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR249
Topic
Patient-Centered Research, Real World Data & Information Systems, Study Approaches
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Rare & Orphan Diseases, Urinary/Kidney Disorders